News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Furiex Pharmaceuticals, Inc. (FURX) Reports Fourth Quarter And Full-Year 2013 Financial Results


3/12/2014 7:29:11 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter and year ended December 31, 2013.

For the year ended December 31, 2013, Furiex recorded total revenues of $71.0 million. This included milestone revenue of $45.0 million, consisting of a $25.0 million regulatory milestone from Takeda Pharmaceuticals Company Limited with respect to the U.S. Food and Drug Administration’s approval of three alogliptin-related products in January 2013, a $10.0 million milestone from Takeda upon the European Marketing Authorization of alogliptin and related products in September 2013, a $5.0 million milestone from Berlin-Chemie AG (Menarini Group) upon the launch of Priligy® in France in March 2013 and a $5.0 million milestone from Menarini upon the launch of Priligy in the United Kingdom in October 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES